Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiroyama, Takayuki, Suzuki, Hidekazu, Tamiya, Motohiro, Tamiya, Akihiro, Tanaka, Ayako, Okamoto, Norio, Nakahama, Kenji, Taniguchi, Yoshihiko, Isa, Shun‐ichi, Inoue, Takako, Imamura, Fumio, Atagi, Shinji, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773945/
https://www.ncbi.nlm.nih.gov/pubmed/29150906
http://dx.doi.org/10.1002/cam4.1234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773945/
https://www.ncbi.nlm.nih.gov/pubmed/29150906
http://dx.doi.org/10.1002/cam4.1234

Ejemplares similares